{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bhat R"],"funding":["Department of Defense BCRP","Breast Cancer Research Foundation","NCI NIH HHS","NIH","NIH HHS"],"pagination":["1972"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8817007"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["G Protein-Coupled Receptors (GPCRs) represent the largest superfamily of cell-surface proteins. However, the expression and function of majority of GPCRs remain unexplored in breast cancer (BC). We interrogated the expression and phosphorylation status of 398 non-sensory GPCRs using the landmark BC proteogenomics and phosphoproteomic dataset from The Cancer Genome Atlas. Neuropeptide Y Receptor Y1 (NPY1R) gene and protein expression were significantly higher in Luminal A tumors versus other BC subtypes. The trend of NPY1R gene, protein, and phosphosite (NPY1R-S368s) expression was decreasing in the order of Luminal A, Luminal B, Basal, and human epidermal growth factor receptor 2 (HER2) subtypes. NPY1R gene expression increased in response to estrogen and reduced with endocrine therapy in "],"journal":["Scientific reports"],"pubmed_title":["NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer."],"pmcid":["PMC8817007"],"funding_grant_id":["W81XWH-14-1-0341","CA125123","W81XWH-14-1-0340","BCRF-18-145","P50 CA186784","CA186784-01","P50 CA058183","BCRF-19-145"],"pubmed_authors":["Nanda S","Trivedi MV","Vasaikar S","Fu X","De Angelis C","Abdulkareem NM","Cataldo ML","Schiff R","Bhat R","Thangavel H","Bae L","Zhang B"],"additional_accession":[]},"is_claimable":false,"name":"NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.","description":"G Protein-Coupled Receptors (GPCRs) represent the largest superfamily of cell-surface proteins. However, the expression and function of majority of GPCRs remain unexplored in breast cancer (BC). We interrogated the expression and phosphorylation status of 398 non-sensory GPCRs using the landmark BC proteogenomics and phosphoproteomic dataset from The Cancer Genome Atlas. Neuropeptide Y Receptor Y1 (NPY1R) gene and protein expression were significantly higher in Luminal A tumors versus other BC subtypes. The trend of NPY1R gene, protein, and phosphosite (NPY1R-S368s) expression was decreasing in the order of Luminal A, Luminal B, Basal, and human epidermal growth factor receptor 2 (HER2) subtypes. NPY1R gene expression increased in response to estrogen and reduced with endocrine therapy in ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-30T15:13:02.493Z","creation":"2025-04-19T22:37:42.827Z"},"accession":"S-EPMC8817007","cross_references":{"pubmed":["35121782"],"doi":["10.1038/s41598-022-05949-7"]}}